Last year, Novo Nordisk A/S generated 23.00B USD for its biggest-performing segment, Total GLP-1. The USA made the largest contribution, accounting for 26.17B USD last year. For the latest quarter, Novo Nordisk A/S reported the revenue of 5.72B USD for the period ending 2026-06-30, which came from the top-performing segment, Total GLP-1. USA contributed the highest revenue, at 6.36B USD.

By Business

Revenue

Proportion

Annual

Annual

Quarterly

Total GLP-1

Obesity (Saxenda®)

Long-acting insulin

Fast-acting insulin

Rare blood disorders

Premix insulin

Rare endocrine disorders (Norditropin)

Human insulin

Other diabetes

Other Rare disease

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

Total GLP-1

23.00B(49.25%)

21.63B(51.35%)

17.87B(53.01%)

11.79B(47.11%)

8.52B(38.07%)

6.40B(32.95%)

4.98B(27.23%)

4.14B(23.36%)

Obesity (Saxenda®)

12.44B(26.64%)

9.45B(22.43%)

6.04B(17.92%)

2.38B(9.53%)

1.34B(5.97%)

857.57M(4.42%)

851.49M(4.65%)

612.43M(3.46%)

Long-acting insulin

2.83B(6.07%)

2.77B(6.58%)

2.16B(6.42%)

2.37B(9.46%)

2.87B(12.83%)

2.82B(14.53%)

3.12B(17.03%)

3.30B(18.64%)

Fast-acting insulin

2.81B(6.01%)

2.69B(6.38%)

2.31B(6.87%)

2.47B(9.87%)

2.81B(12.56%)

2.80B(14.43%)

2.89B(15.82%)

3.06B(17.31%)

Rare blood disorders

1.81B(3.87%)

1.76B(4.18%)

1.71B(5.07%)

1.66B(6.62%)

1.62B(7.26%)

1.48B(7.61%)

1.54B(8.43%)

1.52B(8.56%)

Premix insulin

1.56B(3.34%)

1.56B(3.72%)

1.39B(4.12%)

1.49B(5.97%)

1.78B(7.96%)

1.67B(8.61%)

1.59B(8.67%)

1.61B(9.12%)

Rare endocrine disorders (Norditropin)

900.46M(1.93%)

724.20M(1.72%)

556.75M(1.65%)

1.01B(4.03%)

1.16B(5.19%)

1.18B(6.07%)

1.09B(5.96%)

1.08B(6.11%)

Human insulin

828.68M(1.77%)

1.01B(2.40%)

1.10B(3.27%)

1.16B(4.63%)

1.44B(6.43%)

1.36B(6.99%)

1.35B(7.41%)

1.47B(8.28%)

Other diabetes

267.46M(0.57%)

307.49M(0.73%)

335.56M(1.00%)

455.99M(1.82%)

571.53M(2.55%)

616.41M(3.18%)

636.78M(3.48%)

672.73M(3.80%)

Other Rare disease

255.98M(0.55%)

218.72M(0.52%)

225.11M(0.67%)

240.09M(0.96%)

267.64M(1.20%)

238.55M(1.23%)

243.65M(1.33%)

240.13M(1.36%)

By Region

Revenue

Proportion

Annual

Annual

Quarterly

USA

EUCAN

Emerging Markets

APAC

Region China

EMEA

Rest of World

Canada

Pacifics

Region AAMEO

Japan & Korea

Latin America

North America

International operations

Korea and Japan

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

FY2014

FY2013

FY2012

FY2011

USA

26.17B(56.03%)

24.28B(57.64%)

18.51B(54.91%)

11.97B(47.84%)

10.02B(44.75%)

8.84B(45.55%)

8.62B(47.11%)

8.62B(48.72%)

8.46B(49.98%)

8.50B(51.17%)

8.18B(50.90%)

--(--)

EUCAN

9.99B(21.38%)

--(--)

Emerging Markets

4.60B(9.85%)

--(--)

APAC

3.13B(6.70%)

--(--)

Region China

2.82B(6.04%)

2.68B(6.37%)

2.42B(7.18%)

2.29B(9.16%)

2.55B(11.38%)

2.15B(11.09%)

1.93B(10.53%)

1.79B(10.09%)

1.62B(9.59%)

1.55B(9.36%)

1.47B(9.15%)

1.44B(9.11%)

1.28B(8.57%)

1.11B(8.20%)

933.85M(8.32%)

EMEA

--(--)

8.76B(20.80%)

7.38B(21.90%)

6.25B(25.00%)

6.00B(26.78%)

5.24B(27.02%)

3.49B(19.06%)

3.43B(19.39%)

3.21B(18.97%)

3.07B(18.50%)

3.10B(19.27%)

3.59B(22.69%)

3.57B(24.01%)

3.40B(25.26%)

3.58B(31.88%)

Rest of World

--(--)

4.83B(11.48%)

4.08B(12.09%)

3.59B(14.36%)

3.15B(14.07%)

2.67B(13.74%)

--(--)

Canada

--(--)

1.56B(3.71%)

1.32B(3.92%)

912.13M(3.65%)

676.49M(3.02%)

503.56M(2.59%)

445.46M(2.43%)

383.06M(2.16%)

330.14M(1.95%)

--(--)

6.95B(46.70%)

5.91B(43.86%)

4.96B(44.22%)

Pacifics

--(--)

1.40B(8.41%)

1.27B(7.88%)

--(--)

Region AAMEO

--(--)

2.11B(11.55%)

1.92B(10.87%)

1.82B(10.76%)

2.09B(12.57%)

2.06B(12.80%)

--(--)

Japan & Korea

--(--)

967.54M(5.29%)

917.61M(5.18%)

920.40M(5.44%)

--(--)

946.90M(6.36%)

1.14B(8.48%)

--(--)

Latin America

--(--)

737.09M(4.03%)

634.59M(3.58%)

560.70M(3.31%)

--(--)

North America

--(--)

7.67B(48.56%)

--(--)

International operations

--(--)

2.23B(14.12%)

2.14B(14.37%)

1.91B(14.20%)

1.75B(15.58%)

Korea and Japan

--(--)

872.96M(5.52%)

--(--)